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Non-invasive imaging of the inflammatory process can provide a great deal of insight into a wide 
variety of diseases states, aiding diagnosis, evaluation and effective targeted treatment. During 
inflammation, blood borne leukocytes are recruited, through a series of activation and adhesion 
steps, to the site of injury or infection where they migrate across the blood vessel wall into the 
tissue. Thus, tracking leukocyte recruitment and accumulation provides a dynamic and localised 
read out of inflammatory events. Current leukocyte imaging techniques require ex vivo labelling 
of patient blood, involving laborious processing and potential risks to both patient and laboratory 
staff. Utilising high affinity ligands for leukocyte specific receptors may allow for injectable tracers 
that label leukocytes in situ, omitting potentially hazardous ex vivo handling. Formyl peptide 
receptors (FPRs) are a group of G-protein coupled receptors involved in the chemotaxis and 
inflammatory functioning of leukocytes. Highly expressed on leukocytes, and up regulated during 
inflammation, these receptors provide a potential target for imaging inflammatory events. 
 
Herein we present the synthesis and initial in vitro testing of a potential Single Photon Emission 
Computed Tomography (SPECT) leukocyte tracer. The FPR1 antagonist cFLFLFK-NH2, which 
displays high affinity with little physiological effect, has been linked via a PEG motif to a 99mTc 
chelate. This tracer shows in vitro binding to human embryonic kidney cells expressing the FPR1 
receptor, and functional in vitro tests reveal cFLFLFK-NH2 compounds to have no effect on 
inflammatory cell functioning. Overall, these data show that 99mTc.cFLFLFK-NH2 may be a useful 
tool for non-invasive imaging of leukocyte accumulation in inflammatory disease states. 
  
  
 
 
Introduction 
Single Photon Emission Computed Tomography (SPECT) is a highly sensitive and versatile nuclear medical imaging technique. 
Specifically designed gamma-emitting radiotracers can provide accurate 3D localisation of a desired target or process, providing 
useful diagnostic and prognostic information. SPECT tracers have been widely used e.g. for tumour imaging (indium-111 
octreotide) 1, bone scintigraphy (technetium-99m-MDP) 2 myocardial perfusion imaging (Myoview) 3 and brain functional imaging 
(Ceretec) 4. 
 
The inflammatory response is increasingly being recognised as playing a significant role in a wide variety of disease states 
including; autoimmune diseases such as rheumatoid arthritis 5 and lupus 6, vascular diseases 7, infection, neurodegenerative 
disorders 8 and cancers 9. Effective and non-invasive imaging tools are vital not only in the diagnosis of disease, but also as a 
screening tool to facilitate drug discovery. Imaging of the increased metabolic rate and elevated glucose transporters associated 
with inflammation using fluorine-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) has proved of some use in 
monitoring inflammation. However, FDG is not specific for inflammatory conditions and has a high rate of false-positives 10, 11. 
Similarly, 67Ga-labelled citrate which binds a variety of plasma proteins (including transferrin) and accumulates at sites of 
inflammation, can been used to image inflammatory foci, however, it too suffers from a lack of specificity11.  
 
Neutrophils are the most abundant phagocytic leukocytes in the body, and are the earliest leukocyte subtype recruited to the site 
of tissue damage 9. These cells harbour secretory vesicles containing a variety of cytotoxic substances allowing for a rapid and 
indiscriminate response to pathogens, but in the case of pathogenic inflammation may also damage the body’s own cells. Due to 
their abundance and often pathological role in the inflammatory disorders, tracking this leukocyte subset with a non-invasive 
technique, such as SPECT, may provide a powerful clinical and pre-clinical tool. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of 99mTc.1/Re.1 
  
Formyl peptide receptors (FPRs) are a family of seven transmembrane domain G-protein-coupled receptors (GPCRs), with three 
FPRs (FPR1, FPR2, and FPR3) having been identified in humans 12. Originally identified as a receptor for chemoattractants e.g. 
N-formyl-Met-Leu-Phe (fMLP), FPR1 is a highly abundant cell surface receptor on neutrophils, and is up-regulated under 
inflammatory conditions 13. Consequently FPR1 ligands such as fMLF and i-Boc-MLF have previously been investigated as 
nuclear imaging tracers for neutrophilic inflammation 14. However, these peptides have been found to enhance key inflammatory 
processes such as activation and chemotaxis 15, 16. cFLFLFK-NH2 is a hexapeptide (with a cinnamoyl group at the c-terminus), 
and an antagonist of FPR1, with little reported inflammatory activity 14. 
 
To date, the ‘gold standard’ for radioimaging of inflammation is through ex-vivo cell labelling, where indium-111 or technetium-
99m are bound intracellularly to isolated leukocytes 11, 17. As discussed above, the recruitment of leukocytes to sites of tissue 
damage is a hallmark of the inflammatory response and as such, tracking leukocytes provides a high level of specificity. Ex vivo 
labelling requires processing of blood samples, posing risks of infection for both patient and laboratory staff. Furthermore, 
neutrophils which are highly sensitive to inflammatory activation, may be activated during processing, causing brief but intense 
signal in pulmonary vessels following administration.11 A tracer that could be safely administered to a patient and label leukocytes 
in situ, would have significant benefits over current methodologies. While antibody based strategies have so far proved of limited 
success 18 the use of ligands with high affinity for leukocyte cell surface receptors may prove fruitful.  The cFLFLFK-NH2 peptide, 
modified with a polyethylene glycol (PEG) moiety to increase solubility and bioavailability, has previously been investigated as a 
near infrared (NIR) fluorescence imaging probe using a Cyanine 7 fluorophore 19 and also as a PET imaging agent, being further 
modified with a DOTA motif to chelate the a 64Cu radio-isotope 14, 20. However, the limited tissue-penetration depth of NIR imaging 
and the relatively high cost of PET (along with the requirement for cyclotron facilities for 64Cu production) may limit the use of 
these imaging agents.  Zhang et al. have labelled cFLFLFK-NH2 peptide with 99mTc as a SPECT agent, however their studies use 
coordination through TKPPR. TKPPR is an antagonist of the yet to be fully characterised tuftsin receptor (proposed to be 
neurophilin-1) which has been shown to be expressed on neutrophils, macrophages and also to a high degree on endothelial cells 
and in cancers 21. This lack of specificity and that the target receptor is relatively poorly characterised may limit the use of this 
imaging compound. Furthermore the method of synthesis used only produced  a  radiochemical yield of 75% 22. More recently 
Stasiuk et al. have reported a MRI contrast agent based on cFLFLFK-NH2 and DOTA chelate showing detection of neutrophils in 
an inflammatory response 23. 
In the present study we utilise 99mTc, the most widely used radio-isotope in medicinal imaging, as a gamma emitting tracer. With 
a half-life of 6.5 hours, 99mTc allows for an excellent window of time for imaging whilst also limiting patient exposure24. Furthermore 
the ready availability for production from molybdenum-99 (66 hour half-life and the parent isotope used in technetium generators)  
allows 99mTc to be used in hospitals with limited radiochemistry facilities 24. Here, 99mTc has been encapsulated within an organic 
framework (chelate) and conjugated to the FPR1 ligand, cFLFLFK-NH2.  This novel tetraglycine chelate for 99mTc, produces a 
SPECT tracer which has been assessed in vitro and in vivo. 
 
Results and discussion 
1 was synthesised in 82% yield from tetra glycine and tBOC anhydride, described by Shendage et al. as a general synthesis for 
protection of amino acids (Scheme 1).25 The purification of which was less facile than first anticipated, due to the high water 
solubility of 1 and starting materials. 1 was purified by precipitation of the tetraglycine from the starting material and inorganic salts 
by the addition of MeOH giving a pure product. This is highlighted in the 1H NMR spectrum by the appearance of a 9H singlet at 
1.48 ppm corresponding to the tBOC group and the shift of CH2 groups on the glycine from 3.9 ppm to 3.8 ppm. Further indication 
is observed in the ESMS at 347 [M+H]. 3 has been synthesised with 29% yield, in a two-step reaction from an average weight 
3000 tBOC-NH-PEG-NHS with cFLFLFK-NH2. 3 was produced in situ by the cleavage of the tBOC protecting group with TFA. The 
crude mixture was purified using HPLC, using a gradient of H2O 0.1% TFA: MeCN starting at 95:5 to 5:95 over 30 minutes on a 
c18 reverse phase column. 3 was eluted at 19 minutes, which was confirmed by mass spectrometry MALDI 3609, 3685, 3762, 
range of mass is due to the average weight PEG linker. 4 was synthesised in 71% yield, from the reaction of 3 with 2, under the 
same conditions as formation of 3. 2 was synthesised in situ from 1 and sulfo-NHS in the presence of EDC. 4 was purified via 
reverse phase HPLC on a c18 column, using a gradient of H2O 0.1% TFA: MeCN starting at 50:50 to 5:95 over 20 minutes, with 
a retention time of 4.5 minutes. Formation has been confirmed by MALDI-TOF mass spectrometry (MS) with peaks at 4254, 4298 
and 4342. 
In order to test the tetraglycine chelates affinity for 99mTc, a cold chemistry alternative was devised. Coordination of Re(V)=O with 
4 was undertaken to create a Re=O core in the same coordination environment required for 99mTc. Ammonia perrhenate and 
sodium glutamate in the presence of SnCl2 and HCl gives the desired Re=O core with two glutamate units coordinating. This 
precursor is soluble in water, and formation is indicated by the change of solution colour to blue, to which 4 is added. The 
transmetalation reaction was indicated by a change in colour of solution to yellow, after heating to reflux for 2 h. Purification via 
HPLC, was undertaken and Re.1 has a retention time of 4 minutes, gradient of 50:50 to 5:95 (H2O:MeCN),with a yield of 72%. 
  
 
This was confirmed via MALDI-TOF MS with peaks at 1474, 1499, 1536 [M/3], which is expected for Re.1 with a 3+ charge. The 
mono-oxo core and 3+ charge were verified by the synthesis of the model compound, Re.Tetraglycine which showed a 3+ 
species in the ESMS at 149 [M/3], and a peak in the FT-IR at 943 cm-1, which is indicative of the Re=O bond.26 The complex was 
examined for luminescence, a peak was observed at 440 nm in Figure 1 and shows the emission spectrum (red) for Re.1, a 
Re(V)=O complex, and the excitation spectrum (blue) showing a Ligand to Metal Charge Transfer (LMCT) band at 388 nm. This 
is a comparable emission maxima and excitation wavelength through the LMCT to other Re(V)=O compounds, recently shown by 
Hann and co-workers.27   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Luminescence Spectra for Re.1 emission spectrum (red), excitation spectrum (blue), λex = 388 nm λem = 440 nm, (298K, H2O, pH 7.4).  
 
Synthesis of 99mTc.1 was undertaken with 4 dissolved in a solution of sodium glutamate to which SnCl2, in HCl was added as a 
reductant. 99mTc.O4- (4 mCi) was added to the solution and heated at 80oC for 45 minutes. The solution was passed down a G-
10 Sephedex column to purify and fractions of 0.5 ml were taken and tested for radioactivity in a gamma counter. The radiolabelled 
peptide eluted after 1 column volume. Un-reacted 99mTc was eluted after 2 column volumes. The radiochemical yield was 
determined to be 93% (supplementary S4), suggesting the transmetallation reaction from the 99mTc-bis-glutamate, pre-chelate is 
highly efficient, and that tetraglycine is an excellent novel chelate for 99mTc. Studies at different heating times were undertaken at 
15, 30 and 45 minutes, the largest concentration of 99mTc.1 eluted from the column was observed when heated at 45 minutes. 
This is nearly as efficient as the more standard tetraamine chelates with regards to reaction kinetics for this coordination geometry 
of the 99mTc. 
 
In vitro experiments 
Binding and chemotaxis assays were undertaken using Re.1 to determine the specificity, efficacy and effect on neutrophil 
functional responses of using 99mTc.1 as a SPECT imaging agent, and if the modification to the native cFLFLFK-NH2 peptide 
changed the antagonistic properties.  
In order to validate the specificity of our compounds for FPR1, receptor-binding studies were performed using human embryonic 
kidney (HEK) cells stably transfected with FPR1. A competition binding studies using 125I labelled fnLLFnLYK ([125I]-Form-
NleLeuPheNleTyrLys) revealed Re.1 to have an IC-50 of 18 nM giving the Ki as 9.6 nM as determined using the Cheng-Prusoff 
equation, demonstrating that Re.1 binds FPR1 with an affinity not dissimilar to the native peptide (Kd = 2 nM). This illustrates that 
the choice of conjugation upon the lysine residue does not significantly disrupt the binding to FPR1 and therefore that 99mTc.1 will 
bind with a similar affinity. 
In order to confirm specificity of Re.1 for FPR1 over other neutrophil FPR family members (i.e. FPR2), radioligand binding assays 
were also performed using HEK cells stably transfected with FPR2. Re.1 failed to show any specific binding to FPR2 receptor, 
indicating the specificity of Re.1 for FPR1.  
 
 
 
 
 
 
 
 
  
 
 
 
Figure 2. Competition binding curves of 125I-fnLLFnLYK analogue vs Re.1, A) cFLFLFK-Re demonstrates competitive binding to FPR1 expressing HEK cells, against 
125I fnLLFnLYK, with an IC50 of 18nM and a mathematically derived Kd of nM B) 125I fnLLFnLYK displays a lower level of binding at HEK-FPR2 cells while Re.1 
shows no specific binding to this receptor. Data points represent mean +/- SEM from 4 independently performed experiments.  
 
 
FPR1 is a known neutrophil chemoattractant receptor and administration of biologically active ligands could enhance the 
chemotactic response promoting tissue infiltration and degranulation of leukocytes, enhancing inflammation and tissue damage. 
Thus, in order to ascertain whether any of the cFLFLFK-NH2 compounds elicited a chemotactic response, the level of isolated 
human neutrophil chemotaxis toward these peptides was investigated in comparison to the chemotactic peptide fMLP. Figure 3a 
demonstrates the number of migrating neutrophils in response to the native cFLFLFK-NH2 peptide and Re.1 in comparison to 
fMLP. In agreement with previous publications cFLFLFK-NH2 14 was found not to produce a chemotactic response, with 
concentrations of 0.1-300 nM producing no significant increase in chemotaxis  compared to media alone. Re.1 closely mirrored 
the effects of the native peptide producing little to no chemotactic response demonstrating that conjugation of the native peptide 
to a chelate upon the lysine residue does not confer chemotactic properties to the peptide. 
Figure 3: A) The effect of cFLFLFK-NH2 or Re.1 to induce neutrophil chemotaxis. Freshly  isolated human neutrophils were added to the top wells of a modified 
boyden chemotaxis chamber, whilst different concentrations of the peptides were added to the bottom wells to assess their potential chemotactic effect. fMLP (10 nM. 
Bottom well) demonstrates a significant migration of neutrophils into the bottom well while cFLFLFK-NH2 and Re.1 induce similar levels of chemotaxis as found with 
the vehicle.. Data are overall average  SEM of 4 separate experiments, prepared with different neutrophil donors. Each experiment was run in triplicate. *P<0.01 vs. 
fMLP alone (ANOVA and Bonferroni).  B) Effect of cFLFLFK-NH2 or Re.1 on human neutrophil chemotaxis. neutrophils were  treated with varying concentrations of 
the compounds for 10 minutes prior to addition to the chemotaxis plate where fMLP (10 nM) was added to the bottom wells.. Pre treatment had no significant effect on 
the chemotactic action of fMLP. Data are overall average  SEM of 4 separate experiments, prepared with different neutrophil donors. Each experiment was run in 
triplicate. *P<0.01 vs. fMLP alone. ^ P<0.05 vs. cFLFLFK-NH2 (ANOVA and Bonferroni). 
 
To determine whether cFLFLFK-NH2 or Re.1 had an effect on neutrophil chemotaxis toward fMLP, neutrophils were pre-incubated 
  
 
with these compounds before being exposed to an fMLP gradient (Figure 3b). Treatment with either the native peptide of Re.1 
was found to have no significant effect on the ability of neutrophils to respond to chemotactic signals. These results are promising, 
indicating that the Re.1 tracer will not influence the inflammatory functioning of neutrophils during the process of imaging. 
 
In Vivo SPECT Imaging 
 
To show that 99mTc.1 is a viable probe for imaging FPR1 on neutrophils, an acute murine inflammatory response was 
induced via the injection of lipopolysaccharide (LPS), LPS is a bacterial fragment that disrupts the vascular endothelium, 
causing sites of inflammation and the recruitment of activated neutrophils. C57BL/6 mice were injected with LPS in the 
left thigh and saline in the right thigh 4 hours prior to scanning. This acute inflammation model produces neutrophil 
accumulation in the left thigh and not the right. 99mTc.1 (350-500 uCi) was injected intravenously via the tail vein, and 
allowed to circulate for 30 minutes prior to imaging. Figure 4 (right side of image) shows uptake in the left thigh and not 
the right, showing specific targeting to neutrophils, these initial studies showing the ability of imaging the localisation of 
neutrophils in the thigh are promising. LPS injection is a widely used model of bacterial induced inflammation and is thus 
relevant to infection. In demonstrating that 99mTc.1 can be used to target and image neutrophil accumulation in the thigh, 
we have provided proof of concept that 99mTc.1 may provide as a useful tool to image neutrophilic inflammatory events. 
Due to the involvement of neutrophil accumulation in a wide variety of disease states we aim to test this SPECT tracer 
in different models of both acute and chronic clinically relevant models of inflammatory disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 SPECT image of murine LPS thigh model at 30 minutes after injection with 99mTc.1. 
 
Conclusions 
These studies were undertaken to validate 99mTc.1 as a potential SPECT imaging agent to track neutrophil recruitment and 
accumulation, thus giving a read out of inflammatory status. Here we have successfully shown that tetraglycine can be conjugated 
to cFLFLFK-NH2 via a PEG linker, and to this chelate both Re and 99mTc can be coordinated with an oxo-core, forming 99mTc.1 
and Re.1. Re.1 shows luminescent properties and could feasibly be used to observe cells expressing FPR1 in inflammatory 
disease states as a fluorescent probe. These peptides have been demonstrated to bind to FPR1 expressing cell lines and isolated 
human neutrophils with similar affinity as the native peptide. This shows that 99mTc.1 can be used as a SPECT probe for detecting 
inflammatory accumulation of neutrophils without the need for ex vivo labeling of cells. 
 
An ideal imaging agent should not only display selectivity for the target receptor but should also have no effect on the process 
being imaged, in this case the role of the neutrophil in inflammation. Following successful synthesis of cFLFLFK-NH2 conjugates 
we investigated the effects of all compounds on the functional responses of human neutrophils (via neutrophil chemotaxis towards 
fMLP). In line with previous reports, the native cFLFLFK-NH2 peptide was found to have no chemotactic actions upon neutrophils 
nor was it found to enhance chemotaxis toward fMLP. Furthermore modification of the antagonist at the terminal lysine residue 
does not change the chemotactic response of neutrophils with the compounds tested (Re.1, 99mTc.1 and cFLFLFK-NH2). These 
in vitro tests of neutrophil functioning suggest that the compounds produced have no influence on the functional response of 
neutrophils and are thus suitable candidates for non-invasive imaging of neutrophil accumulations in inflammatory diseases. In 
vivo studies show that 99mTc.1 goes to the site of inflammation, allowing for the non-invasive imaging of neutrophil accumulation. 
  
 
In conclusion, these studies reveal that, successful modification of cFLFLFK-NH2 peptide to incorporate the tetragylcine motif as 
a chelate for Re(V), and 99mTc does not abolish ligand affinity for FPR1, nor does it alter specificity for this receptor. Furthermore 
these compounds do not interfere with neutrophil functions, thus demonstrating the potential of these FPR1 ligand analogues as 
possible replacements for current techniques for the non-invasive imaging of inflammation. 
 
Experimental 
Synthesis  
General procedures  
NMR spectra were recorded on an Advance DMX 400 Bruker spectrometer. Chemical shifts are reported in ppm with solvent as 
internal reference. HPLC was carried out on a HP 3000 system with a reverse phase c18 semi prep column. Electronic absorption 
spectra were recorded on a Varian CARY 50 probe UV/vis spectrometer. SPECT/CT scans were performed using a TriFoil 
Imaging Triumph Tri-Modality scanner 
 
Materials 
Solvents and starting materials were obtained from Aldrich, Fluka, Acros, and Alfa. The peptide cFLFLFK-NH2 Cambridge 
biochemical. They were used without further purification unless otherwise stated. Water and H2O refer to high purity water with 
resistivity value of 18 MΩ·cm, obtained from the “Millipore/MilliQ” purification system.  
 
tBOC-tetraglycine 1 
Tetraglycine (0.1 g, 0.4 mmol) was dissolved in H2O and tetrahydrafuran 1:1 (2 ml), cooled to 0oC, to this solution tBOC-anhydride 
(0.11 ml, 0.48 mmol) and NaHCO3 (101 mg, 1.2 mmol) were added sequentially. The solution was stirred for 30 minutes at 0oC, 
then the solution was allowed to warm to room temperature and stirred for 12 h. The mixture was washed with diethyl ether (3 x 
5 ml), the aqueous layer was acidified to pH 5 with dilute HCl and washed with DCM (3 x 5 ml) to remove excess tBOC-anhydride. 
The aqueous layer was then concentrated giving a white solid, which was taken up in MeOH (10 ml) and filtered. The filtrate was 
concentrated yielding a white solid 128 mg (82%) δH (400 MHz, MeOD), 1.61 (9H, s), 3.75 (2H, s), 3.95 (2H, s), 4.15 (2H, s), 4.25 
(2H, s), m/z (ESMS+) 346 [M + H]+. 
 
NHS-tetragylcine- tBOC 2 
1 (80 mg, 0.23 mmol) was dissolved in H2O (5 ml) at pH 8 to which N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (41 mg, 0.23 
mmol) and sulfonyl N-Hydroxysuccinimide (50 mg, 0.23 mmol) were added sequentially at 0oC. This solution was stirred for 1 h 
and allowed to warm up to room temperature. The solution was washed with diethyl ether (3 x 5 ml) and the aqueous phase was 
concentrated yielding a white hydroscopic solid. 
 
cFLFLFK-PEG 3 
cFLFLFK-NH2 (10 mg, 100 µmol) dissolved in MeCN (1 ml) and NHS-PEG-NH-tBOC (31 mg, 100 µmol) dissolved in sodium 
borate buffer (1 ml, pH 8.5) were combined and stirred for 12 hours at 4oC. The solvent was concentrated, giving a white solid to 
which TFA (2 ml) was added. This solution was stirred at room temperature for 2 hours followed by the concentration of the solvent 
to give a white solid, which was purified via HPLC using a c18 reverse phase column with a gradient of H2O 0.1% TFA: MeCN 
starting at 95:5 to 5:95 over 30 minutes. 3 has a retention time of 19 minutes, giving a white solid 12 mg, 29% yield. m/z (MALDI) 
[M+H]+ 3609, 3685, 3762. 
 
cFLFLFK-PEG-tetraglycine 4 
To a solution of 2 (0.42 mg, 0.0013 mmol) in H2O (0.5 ml) 4 (5 mg, 0.0013 mmol) was added in Na borate buffer (0.5 ml) and this 
solution was stirred at 4oC for 12 h. The solvent was removed and the crude solid was purified via HPLC using a c18 reverse 
phase column with a gradient of H2O 0.1% TFA: MeCN starting at 50:50 to 5:95 over 20 minutes. 4 has a retention time of 4.5 
minutes, giving a white solid 2.6 mg, 41% yield. m/z (MALDI) [M+H]+ 4254, 4298 ,4342.  
 
Re cFLFLFK Re.1 
Ammonium perrhenate (0.16 mg, 0.069 mmol) was dissolved in a solution of sodium glutamate (0.5 M, 0.0545 g, 0.5 ml). This 
solution was degassed for 10 minutes, to which SnCl2 (0.139 mg, 0.069 mmol), in HCl (0.1 M, 0.04 ml) was added. The solution 
turned blue, and was stirred for 90 minutes. To the solution 4 (2.6 mg, 0.069 mmol) was added and this solution was heated to 
reflux for 2 h, in which time the solution turned yellow. The solvent was removed giving a yellow solid which was purified via HPLC 
  
 
using a c18 reverse phase column with a gradient of H2O: MeCN starting at 50:50 to 5:95 over 20 minutes. The retention time 
was 4 minutes giving a yellow oil, 2 mg, 73% yield. m/z (MALDI) [M/3]+ 1474, 1499, 1536.  
 
Re tetraglycine  
Ammonium perrhenate (100 mg, 0.37 mmol) was dissolved in a solution of sodium glutamate (0.5 M, 1.09 g, 10 ml). This solution 
was degassed for 10 minutes, to which SnCl2 (71 mg, 0.37 mmol), in HCl (0.1 M, 0.8 ml) was added. The solution turned blue, 
and was stirred for 90 minutes. To the solution tetraglycine (92 mg, 0.37 mmol) was added and this solution was heated to reflux 
for 2 h, in which time the solution turned yellow. The solvent was removed giving a yellow solid which was purified via HPLC using 
a c18 reverse phase column with an isocratic mixture of of H2O: MeCN 95:5 over 20 minutes. The retention time was 3.2 minutes 
giving a yellow oil, 120 mg, 73% yield. δH (400 MHz, D2O), 3.61 (2H, s), 3.67 (2H, s), 3.82 (2H, s), 3.88 (2H, s), FT-IR, (cm-1): 
943 (Re=O) m/z (ESMS) [M/3]+ 149. 
 
99mTc cFLFLFK 99mTc.1 
4 (100 g, 0.02 mmol) was dissolved in a solution of sodium glutamate (0.5 M, 200 l), to which SnCl2 (4.5 mg, 0.02 mmol), in 
HCl (0.1 M, 20 l) was added. 99mTcO4- (4 mCi, 500 l) was added to the solution and heated at 80oC for 45 minutes. The solution 
was passed down a G-10 Sephadex column to purify (2.1 ml), fractions of 0.5 ml were taken and tested for radioactivity using a 
gamma counter. The radiolabelled peptide eluted after 1 column volume. Un-reacted 99mTc was eluted after 2 column volumes. 
 
In vitro experiments 
 
Human blood leukocyte isolation 
The local research committee approved experiments with healthy volunteers, and informed consent was provided according to 
the Declaration of Helsinki. Blood was collected from healthy volunteers with a 21-gauge needle and transferred to a 50 ml 
centrifuge tube containing 1/10 volume of 3.2% sodium citrate. Blood was diluted 1:1 with warm Roswell Park Memorial Institute 
(RPMI) 1640 medium before addition to a double density gradient of equal volumes (3 ml) of Histopaque 1077 over Histopaque 
1119.  Samples were then centrifuged at 400 g for 30 minutes at room temperature. Two distinct layers of leukocytes can be seen 
after centrifugation, with red blood cells (RBCs) pelleted to the bottom of the centrifuge tube. The resulting neutrophil cell layer 
was removed and placed in 6 ml aliquots in 15 ml centrifuge tubes to which an equal volume of RPMI 1640 was added. Samples 
were centrifuged at 300 x g for 15 minutes. The supernatant was then discarded and cells re-suspended with 7.5 ml of ice-cold 
H2O, to lyse any contaminating RBCs, before immediately adding 2.5 ml of 3.6% sodium chloride solution, to restore isotonicity. 
Cells were then centrifuged at 300 x g for 10 minutes and re-suspended in 3 ml of RPMI medium, supplemented with 10% heat 
inactivated foetal calf serum (FCS), L-glutamine (2 mM), penicillin (100 U) and streptomycin (100mg/ml) (complete media). Cell 
counts were performed in Turk’s solution (1:10) using a haemocytometer and cells diluted to the appropriate concentration for 
each assay using complete media. 
 
Compound Preparation 
cFLFLFK-NH2 and Re.1 were made in-house and on the day of the experiment were dissolved in pre-warmed PBS to make a 
stock concentration of 1 μM and diluted in RPMI1640 0.1% BSA to the desired concentrations. formyl-Met-Leu-Phe (fMLP), a pro-
inflammatory ligand of FPRs, and peptide Ac2-26, LXA4, and ionomycin were all used as controls.  
 
Receptor binding studies 
Human Embryonic Kidney (HEK293) cells transfected to express FPR1 under the CMV promoter were grown to confluence in 
Dulbecco's Modified Eagle Medium (DMEM) plus L-glutamate containing 10% FCS, 0.05ug/ml gentamicin and 0.2 mg/ml 
geneticin. Cells were detached using 0.5mM EDTA in Dulbecco's Phosphate-Buffered Saline before being centrifuged at 1200rpm 
for 5 minutes and re-suspending in RBA buffer (1 M HEPS buffer + 6 µM CaCO3 + 2 µM MgCO3 + 0.5% BSA) and used at 1x105 
cells per assay. Saturation curves were initially performed using the radio labeled ligand [125I]-fNleLeuPheNleTyrLys (Cambridge 
Research Biochemicals, UK custom labeled by Perkin Elmer). Kd was determined using a one site saturation curve fit in Graphpad 
prism 5 giving a Kd of 68,350 cpm. This confirmed receptor binding to the FPRs and to inform the concentration to be use in 
competition assays.  For competition binding studies, 400 µl of cell suspension was incubated with 50µl of a fixed concentration 
of  [125I]-Form-NleLeuPheNleTyrLys (60,000 cpm) and 50µl of RBA buffer containing various concentrations of Re.1, (from 1x10-
5 M – 1x10-10 M ). Following 90 minutes incubation with radio ligand (in 50µl) at room temperature, cells were centrifuged for 2 
minutes at 2000 RPM, the supernatant  discarded and pellet re-suspended in 0.5 ml RBA buffer before being centrifuged for a 
further 2 minutes at 2000 RPM. The supernatant was then discarded and radiation in the cell pellet measured on a Packard Cobra 
II Gamma Counter for 240 seconds. Binding was expressed as counts per minute (cpm) with IC50 determined using a binding 
competitive one site fit log IC50 curve. Ki was determined using the Cheng-Prusoff equation, where the fixed concentration of 
labelled ligand was 60,000 and Kd was 68,350 cpm.   
  
 
Chemotaxis 
PMN (4x106 /ml in RPMI containing 0.1% BSA) were pre-incubated for 10 minutes with compounds (cFLFLFK-NH2, Re.1 and or 
controls) at 37°C. The chemotaxis assay was performed using commercially available Neuroprobe ChemoTx plate 96-well plates 
(3 µm) (Receptor Technologies Ltd, Warwick, U.K.) with fMLP (10 nM, Sigma Aldrich) as the chemotactic stimulus (concentration 
chosen from preliminary studies, in order to obtain ~85% of the maximal response). Thus, fMLP or medium were added to the 
bottom wells (27 μl), the filter was placed on top and 25 μl of the neutrophil cell suspension placed above the membrane. In some 
cases, cFLFLFK-NH2, and cFLFLFK-Re were added to the bottom well to determine whether these compounds may act as chemo-
attractants themselves. Chemotaxis plates were incubated for 90 minutes at 37C and 5% CO2 in a humidified incubator. After 
incubation any remaining cells were removed using cotton wool buds and the plate was washed with RPMI + 0.1 % BSA. The 
plate was then centrifuged at 312 g for 5 minutes to pellet the migrated cells into the plate wells. The polycarbonate filter was 
carefully removed and the pellets were re-suspended. A 20 l aliquot was taken and diluted 1:10 in Turks solution for counting on 
a haemocytometer, viewed under a light microscope. 
 
In vivo SPECT imaging 
 
99mTc.1 (350 - 500 Ci) in 300l of saline, was injected intravenously via the tail vein of a C51BL6 mouse, which had been injected 
with LPS (10 g/mouse) in the left thigh and saline solution in the right thigh, 4 hours prior to scanning. The contrast agent was 
allowed to circulate for 30 minutes prior to scanning SPECT and CT for 30 minutes using a TriFoil Imaging Triumph Tri-Modality 
scanner. Image acquisition was performed using Triumph X-O® CT and SPECT imaging system software and images rendered 
using Volumetric Image Visualization Identification and Display VIVIDTM software (TriFiol, USA).  
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